Probi AB (publ)

Stockholm Stock Exchange PROB.ST

Probi AB (publ) Shareholders' Equity for the year ending December 31, 2023: USD 135.13 M

Probi AB (publ) Shareholders' Equity is USD 135.13 M for the year ending December 31, 2023, a 0.31% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Probi AB (publ) Shareholders' Equity for the year ending December 31, 2022 was USD 134.71 M, a -3.32% change year over year.
Probi AB (publ) Shareholders' Equity for the year ending December 31, 2021 was USD 139.34 M, a 3.09% change year over year.
Probi AB (publ) Shareholders' Equity for the year ending December 31, 2020 was USD 135.16 M, a 10.26% change year over year.
Probi AB (publ) Shareholders' Equity for the year ending December 31, 2019 was USD 122.59 M, a 5.96% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Stockholm Stock Exchange: PROB.ST

Probi AB (publ)

CEO	Ms. Anita Johansen
IPO Date	Dec. 2, 2004
Location	Sweden
Headquarters	Ideongatan 1A
Employees	157
Sector	Consumers Staples
Industries Non-Alcoholic Beverages Alcoholic Beverages Biotechnology Cosmetics Food & Beverages Pharmaceuticals Soft Drinks & Sodas Vaccines

Description

Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Örebro University for research into exploration needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian women. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.

Key trends

Past 5 years